Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Endometriosis is a chronic estrogen and progestogen responsive inflammatory disease associated with pain symptoms and infertility. The medical therapy of endometriosis aims to induce decidualization within the hormonally dependent ectopic endometrium, and it is often administered to ameliorate women' pain symptoms or to prevent post-surgical disease recurrence. A variety of progestins have been used in monotherapy for the medical management of women with endometriosis. Areas covered: This review aims to offer the reader a complete overview of pharmacokinetic (PK) and clinical efficacy of progestins for the treatment of endometriosis. Expert opinion: Each progestin has a distinct PK parameters and pharmacodynamics affinity not only for progesterone receptor, but also for other steroid receptors, such as estrogen, androgen, and glucocorticoid. Moreover, progestins can also be delivered in different formulations. All these characteristics influence their final biological effect. Randomized, controlled, non-blinded studies support the use of oral progestin-only treatment for pelvic pain associated with endometriosis. Currently, the only two progestins approved by Food and Drug Administration (FDA) for the treatment of endometriosis are norethindrone acetate (NETA) and depot medroxyprogesterone acetate (DMPA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, they have antiestrogenic effect causing endometrial pseudodecidualisation, inhibit inflammatory response, provoke apoptosis of endometriotic cells, reduce oxidative stress, inhibit angiogenesis and suppress expression of matrix metalloproteinases [5, 26] (Fig. 4).”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Pathogenesis and pathophysiology of endometriosis
Burney, R. O., & Giudice, L. C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.029 · Cited by 1,590
Guerriero, S., Condous, G., van den Bosch, T., Valentin, L., Leone, F. P. G., Van Schoubroeck, D., Exacoustos, C., Installé, A. J. F., Martins, W. P., Abrao, M. S., et al. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15955 · Cited by 900
Self-citationStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 2×
“at lumbar spine, respectively) following a 6-month treatment with DNG [94,103].”
BackgroundPetta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363 · cited 10×
“Furthermore, DMPA is often accompanied by unintentional weight gain, loss of libido, which might adversely affect a woman’s QoL and preclude long-term use.”
BackgroundInfluentialThe effect of surgery for symptomatic endometriosis: the other side of the story
Vercellini, P., Crosignani, P. G., Abbiati, A., Somigliana, E., Viganò, P., & Fedele, L. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn062 · Cited by 339
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290 · cited 6×
“Furthermore, urinary symptoms disappeared in all the patients and there was a significant size decrease of bladder nodules at TVS after 3 and 12 months of treatment [97].”
BackgroundInfluentialHarada, T., Momoeda, M., Taketani, Y., Aso, T., Fukunaga, M., Hagino, H., & Terakawa, N. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.080 · Cited by 279
Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis
Reis, F. M., Petraglia, F., & Taylor, R. N. (2013) · Human Reproduction Update · doi:10.1093/humupd/dmt010 · Cited by 275
Research works printed but not linked: 10
- Moran C, 1996, Arch Med Res, 27, 535
- Ponpuckdee J, 2005, J Med Assoc Thai, 88, S7
- Roland M, 1976, J Reprod Med, 17, 249
- Moghissi KS, 1976, Obstet Gynecol, 47, 265
- Luciano AA, 1988, Obstet Gynecol, 72, 323
- 10.1080/j.1600-0412.2001.800708.x · DOI
- Brown J, 2012, Cochrane Database Syst Rev, CD002122
- Lang J, 2017, J Womens Health (Larchmt)
- Vercellini P, 2015, Fertil Steril
- Strowitzki T, 2015, Int J Women’s Health, 7, 391
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
“The choice of the most appropriate therapy is based on the intensity of pain, age, desire to conceive, but also on the impact of the disease on QoL on each patient [26].”
BackgroundHung, S. W., Zhang, R., Tan, Z., Chung, J. P. W., Zhang, T., & Wang, C. C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21802 · Cited by 167
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Self-citationBarra, F., Scala, C., Biscaldi, E., Vellone, V. G., Ceccaroni, M., Terrone, C., & Ferrero, S. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy027 · Cited by 138
Self-citationCurrent and Emerging Therapeutics for the Management of Endometriosis
Ferrero, S., Barra, F., & Maggiore, U. L. R. (2018) · Drugs · doi:10.1007/s40265-018-0928-0 · Cited by 155
Self-citation
Metadata
- Authors
- Barra, F., Scala, C., & Ferrero, S.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Ferrero, Simone
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2018-04-03
- Volume
- 14
- Issue
- 4
- Pages
- 399-415
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2795797649
- Cited by
- 100
- References
- 119
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 10 · 2023: 26 · 2022: 15 · 2021: 14 · 2020: 11 · 2019: 4 · 2018: 5
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- endometriosis, progestins, pharmacokinetics, pharmacodynamics, pelvic pain, norethindrone acetate, depot medroxyprogesterone acetate, progesterone receptor, drug formulation, drug safety
- MeSH terms
- Norethindrone Acetate, Administration, Oral, Endometriosis, Female, Humans, Norethindrone, Progestins, Receptors, Steroid, Randomized Controlled Trials as Topic, Medroxyprogesterone Acetate, Pelvic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. https://app.cochat.ai/papers/10.1080/17425255.2018.1461840
- The paper
- Barra, F., Scala, C., & Ferrero, S. (2018). Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2018.1461840
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.